Palvella Therapeutics Inc (PVLA)

06:01 AM

Palvella Therapeutics Inc. Stock Analysis and ForecastOutstanding capital appreciation - Autocar Professional

06:01 AM

09:41 AM

Palvella Therapeutics Inc (PVLA) Stock: A Year of Highs and Lows in the Market - investchronicle.com

09:41 AM

09:32 AM

A Great Week for Institutional Investors Who Own 27% of Palvella Therapeutics, Inc. (NASDAQ:PVLA) - 富途牛牛

09:32 AM

05:33 AM

Is Palvella Therapeutics Inc. a good long term investmentHigh-yield portfolio picks - Autocar Professional

05:33 AM

Jul 22, 2025

What analysts say about Palvella Therapeutics Inc. stockHigh-yield portfolio picks - jammulinksnews.com

Jul 22, 2025

Jul 21, 2025

Truist Securities initiates Palvella Therapeutics stock with Buy rating By Investing.com - Investing.com Canada

Jul 21, 2025

Jul 20, 2025

What drives Palvella Therapeutics Inc. stock priceSuperior stock growth - jammulinksnews.com

Jul 20, 2025

Jul 15, 2025

What makes Palvella Therapeutics Inc. stock price move sharplyLow Risk Consistent Winners - Newser

Jul 15, 2025

Jul 15, 2025

Why Palvella Therapeutics Inc. stock attracts strong analyst attentionLow Risk Entry Points - Newser

Jul 15, 2025

Jul 15, 2025

How Palvella Therapeutics Inc. stock performs during market volatilityTop Performing Low Risk Stocks - Newser

Jul 15, 2025

Jul 11, 2025

Palvella Therapeutics Secures New Patent for QTORIN™ Rapamycin - MSN

Jul 11, 2025

Jul 09, 2025

Palvella Therapeutics Completes Enrollment for Pivotal Phase 3 Trial of QTORIN Rapamycin - Insider Monkey

Jul 09, 2025

Jul 04, 2025

Is Palvella Therapeutics (NASDAQ:PVLA) A Risky Investment? - simplywall.st

Jul 04, 2025

Jul 03, 2025

Palvella Therapeutics, Inc. (NASDAQ:PVLA) Given Consensus Recommendation of “Buy” by Analysts - Defense World

Jul 03, 2025

Jul 02, 2025

2,516 Shares in Palvella Therapeutics, Inc. (NASDAQ:PVLA) Purchased by Spire Wealth Management - Defense World

Jul 02, 2025

Jul 01, 2025

Palvella Therapeutics Joins Russell 3000 and Russell 2000 Indexes - MSN

Jul 01, 2025

Jun 30, 2025

Palvella Therapeutics, Inc.(NasdaqCM: PVLA) added to Russell 3000 Value Index - MarketScreener

Jun 30, 2025

Jun 30, 2025

Palvella Therapeutics, Inc. Added to Russell 3000® and Russell 2000® Indexes as of June 30, 2025 - Nasdaq

Jun 30, 2025

Jun 24, 2025

Palvella Therapeutics Announces Completion of Phase 3 SELVA Trial for QTORIN Rapamycin - MyChesCo

Jun 24, 2025

Jun 23, 2025

Breakthrough Therapy: Phase 3 Trial Exceeds Target by 25% for First-Ever Microcystic LM Treatment - Stock Titan

Jun 23, 2025

Jun 18, 2025

Palvella Therapeutics Receives US Patent for Qtorin Topical Gel Candidate - MarketScreener

Jun 18, 2025

Jun 18, 2025

Palvella Therapeutics Granted Sixth U.S. Patent Covering - GlobeNewswire

Jun 18, 2025

Jun 18, 2025

Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1-20% Anhydrous Compositions of Rapamycin and Other mTOR Inhibitors - The Manila Times

Jun 18, 2025

Jun 18, 2025

Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1–20% Anhydrous Compositions of - Bluefield Daily Telegraph

Jun 18, 2025

Jun 18, 2025

Palvella's Game-Changing QTORIN Patent Locks in 15+ Years of Market Protection for Rare Disease Treatment - Stock Titan

Jun 18, 2025

Jun 12, 2025

Palvella Therapeutics Secures FDA Grant Funding for Phase 3 Trial of QTORIN Rapamycin - MSN

Jun 12, 2025

Jun 12, 2025

Cantor Fitzgerald Weighs in on PVLA FY2026 Earnings - Defense World

Jun 12, 2025

Jun 11, 2025

Palvella Therapeutics Holds Annual Stockholders Meeting - TipRanks

Jun 11, 2025

Jun 11, 2025

Palvella Therapeutics (NASDAQ:PVLA) Receives $46.29 Consensus Price Target from Analysts - Defense World

Jun 11, 2025

Jun 09, 2025

Palvella Therapeutics receives FDA grant for rare disease trial By Investing.com - Investing.com South Africa

Jun 09, 2025

Jun 09, 2025

Palvella Therapeutics Says Top-Line Data From SELVA Expected In Q1 2026 - marketscreener.com

Jun 09, 2025

Jun 09, 2025

Palvella Therapeutics receives FDA grant for rare disease trial - Investing.com

Jun 09, 2025

Jun 09, 2025

Palvella Therapeutics Receives Initial Proceeds from FDA - GlobeNewswire

Jun 09, 2025

Jun 09, 2025

Citadel Advisors LLC Makes New Investment in Palvella Therapeutics (NASDAQ:PVLA) - Defense World

Jun 09, 2025

Jun 01, 2025

Palvella Therapeutics Names Ashley Kline Chief Commercial Officer - MSN

Jun 01, 2025

May 30, 2025

Palvella Therapeutics Advances in Rare Skin Disease Therapies - TipRanks

May 30, 2025

May 30, 2025

A great week for institutional investors who own 26% of Palvella Therapeutics, Inc. (NASDAQ:PVLA) - simplywall.st

May 30, 2025